Piśmiennictwo

1.Dutkiewicz S. Łagodny rozrost stercza, w: Dutkiewicz S. red. Choroby stercza (gruczołu krokowego). Wyd. Med. Termedia, Poznań, 2010,(155-223).
2.Cruz F, Desgrandchamps F. New concepts and pathophysiology of lower urinary tract symptoms in men. Eur Urol2010;suppl.9: 472-476.
3. Oelke M, Baard J, Wijkstra H, et al. Age and bladder obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54:419-426.
4.Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary symptoms in five countries: results of the EPIC study. Eur Urol 2006; suppl 6:1306-1314.
5.Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Am J Obstet Gynec 2002; 187: 116-126.
6.Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 2011; 95:87-100.
7. Roehrborn CG. The utility of serum PSA in the management of men with benign prostatic hyperplasia. Int J Impot Res 2008; 20(suppl.3):19-26.
8.Verhamme KMC,Dieleman JP, BleuminkGS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 2002; 42: 323-328.
9. Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterisation of patients and ultimate outcomes. The PLESS Study Group.Eur Urol 2000; 37: 528-536.
10. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 2011;95: 87-100.
11.Sarma AV, Jacobson DJ, Mc Gree ME, et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmstead County , Minnesota 1987 to 1997. J Urol 2005; 173: 2048-2053.
12.AUA Practice Guide lines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-547.
13.Chapple Ch. Overview of evidence for contemporary management of lower urinary tract symptoms presumed due to benign prostatic hyperplasia in males. Eur Urol 2010; suppl.9: 482-485.
14.Dorsam J, Altwein J. 5 alpha-reductase inhibitor treatment of prostatic diseases: background and practical implications.Prostate Cancer Prostatic Dis 2009; 12: 130-136.
15.Issa MM, Runken MCh, Grogg AL, et al. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5 alpha-reductase inhibitors: Dutasteride versus Finasteride. Am J Manag Care 2007; 13: 10-16.
16.Nickel JC. Comparison of clinical trials with with finasteride and dutasteride. Reviews in Urology 2004; 6(suppl9): 31-39.
17.Marberger M. The MTOPS Study: New findings, new insight, and clinical implications for the management of BPH. Eur Urol Suppl 2006; 5: 628-633.
18.Kaplan SA, Roehrborn CG, McConnelJD, et al. Baselines symptoms uroflow, uroflow and post-voiding residual urine as predictors of BPH clinical progression in the medically treated arms of MTOPS trial.J Urol 2003; 169 (suppl), abstr.1289.
19.Kirby RS, Roehrborn CG, Boyle P, et al. Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride , alone and combination, in treatment of symptomatic benign prostatic hyperplasia :The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology2003; 61:119-126.
20. Roehrborn CG, Siami P, Barkin J, et al. The effect of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms in men with prostatic enlargement: Two years results from the Combination of Avodart and tamsulosin (COMBAT)study.J Urol2008; 179: 616-621.
21. Gonzalez RR, Te AE. Overactive bladder and men: Indications for aniicholinergics. Curr Urol Rep 2oo3; 4(6):429-435.
22. Athanasopoulos A, Gyftopoulos K, Gianitsas K, et al. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction: A prospective randomized controlled study. J Urol 2003; 169: 2253-2256.
23. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 326-332.
24. Masumori N, Tsukamoto T, Yanase M, et al. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symtoms suggestive of benign prostatic obstruction. Adv Urol 2010; 250-251.
25. Delke M, Bachmann CG, Descazeaud A, et al. European Association of Urology guidelines 2010 ed. Guidelines on conservative treatment of non-neurogenic male LUTS, s. 29-36.
26. Buchara A, Romano S, Casabe A, et al. Comparative efficacy assessement of tamsulosin vs,\. Tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5(9):2170-2178.